Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
Past Issue

Vol. 12, No. 3
March 2006

Adobe Acrobat logo

EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

PDF Version | Comments Comments | Email this article Email this article



Acknowledgments
References
Figure
Appendix Figure
Appendix Table

Letter

Rickettsia slovaca Infection, France

Frédérique Gouriet,* Jean-Marc Rolain,* and Didier Raoult*Comments
*Université de la Méditerranée, Marseille, France

Suggested citation for this article


To the Editor: Rickettsia slovaca was first isolated in 1968 in a Dermacentor marginatus tick collected in Slovakia, and serologic evidence of infection with this bacteria was reported in patients with enlarged lymph nodes and a scalp eschar after being bitten by a tick (1). However, the first proven case of R. slovaca infection was reported only in 1997 in France (2). This rickettsiosis is called tickborne lymphadenopathy (TIBOLA) because the most pronounced sign is lymph node enlargement. In Spain the same condition is called Dermacentor-borne-necrosis-erythema lymphadenopathy (3,4).

Figure
Figure.

Click to view enlarged image

Figure. Seasonal distribution of Mediterranean spotted fever (MSF) and tickborne lymphadenopathy (TIBOLA)...

 
Appendix Figure
Appendix Figure.

Click to view enlarged image

Appendix Figure. Patients with Rickettsia slovaca infection...

In this study, we describe 14 new patients with TIBOLA from southern France who sought treatment from January 2004 to May 2005 and compare the features of these patients with those in whom Mediterranean spotted fever (MSF) was diagnosed during the same period. All the patients were referred to our center with a suspected rickettsial infection characterized by a tick bite located on the scalp, an inoculation eschar, and enlarged lymph nodes (Appendix Figure). For each patient, an acute-phase and a convalescent-phase serum sample were obtained for serologic analysis. Culture and polymerase chain reaction (PCR) were performed on tick, skin biopsy, or blood specimens. A multiple-antigen immunofluorescence assay (IFA) was performed by using 5 spotted fever group (SFG) rickettsial antigens: R. conorii conorii, R. slovaca, R. helvetica, R. sibirica mongolitimonae, and R. felis. Titers of at least 64 for immunoglobulin G (IgG) and 32 for IgM in acute-phase serum samples, evidence of seroconversion with 4-fold increases in IgG titers, or both, were considered as evidence of recent infections with a Rickettsia sp. (5). For serum specimens confirmed by IFA at the species level, Western immunoblotting and cross-adsorption assays procedures were performed as described elsewhere (6) by using R. conorii conorii and R. slovaca antigens. Patients with a definite serologic diagnosis at the species level were analyzed for their epidemiologic and clinical information.

Culture from skin biopsy specimen and ticks were injected into human embryonic lung cells and cultivated into shell-vial culture as previously described (7). DNA was extracted from skin biopsy specimens, acute-phase serum samples, and ticks by using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) (8). Standard PCR was performed with primers suitable for hybridization within the conserved region of genes coding for outer membrane protein A (ompA) and citrate synthase (gltA) (8).

Among the 14 patients in a scalp lesion and cervical or occipital (1 case) lymph node enlargement developed after they were bitten by a tick, 9 were female (1 was pregnant) and 5 were male. The median (range) age was 34.9 (5-85) years with half of the patients <10 years of age. The incubation period ranged from 5 to 15 days (median 10.5 days; n = 7). Only 3 patients had fever. All patients fully recovered with doxycycline or, for the pregnant patient, josamycin therapy. Serology confirmed the diagnosis of R. slovaca infection for 10 patients by microimmunofluorescence and Western blot analysis after cross-adsorption studies (Appendix Table). R. slovaca was amplified by PCR for 7 cases, including 3 skin biopsy specimens, 3 Dermacentor marginatus ticks, and 1 acute-phase serum sample (Appendix Table). Three isolates (2 from skin biopsy specimens and 1 from a tick) were obtained by using the shell-vial culture assay. During the period of our study, in the same French region, 40 patients with MSF were clinically and laboratory diagnosed using the same procedures. The median (range) age was 54.2 (5–85) years with only 3 children <10 years of age (compared to 7/7 children with R. slovaca infection, p = 0.0015). MSF occurred mainly during the summer, whereas R. slovaca infection was seen during the colder months with 6 cases from October to January and 8 cases from February to May (Figure).

In France, R. conorii has long been considered to be the only SFG rickettsiosis but R. slovaca may also be prevalent (9), contributing 25% of the cases in the present study. This organism is also a common cause of disease in Hungary and in La Rioja, Spain (3). These data suggest that TIBOLA mainly occurs in young children, affects women predominately, and occurs primarily during the colder months (9,10). As previously reported (9), we found that standard microimmunofluorescence serologic testing was insensitive and that Western blot is more useful and allows identification to the species level after cross-adsorption studies. Finally, DNA amplification by PCR from skin biopsy tissue, serum samples, or in ticks allowed confirmation of the diagnosis in only 50% of the cases, which suggests that other rickettsial species may be responsible for TIBOLA. Epidemiologic and clinical presentations are so characteristic that the clinical diagnosis should be considered in patients who have been bitten on the scalp during the colder months. In Europe, R. slovaca infection is likely to be a significant cause of cervical lymph node enlargement, and microbiologic investigation and tick analysis will underline the relative importance of this disease.

Acknowledgments

We thank Paul Newton for reviewing the manuscript.

References

  1. Raoult D, Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev. 1997;10:694–719.
  2. Raoult D, Berbis P, Roux V, Xu W, Maurin M. A new tick-transmitted disease due to Rickettsia slovaca. Lancet. 1997;350:112–3.
  3. Parola P, Paddock CD, Raoult D. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev. 2005;18:719–56.
  4. Oteo JA, Ibarra V, Blanco JR, Martinez dA, V, Marquez FJ, Portillo A, et al. Dermacentor-borne necrosis erythema and lymphadenopathy: clinical and epidemiological features of a new tick-borne disease. Clin Microbiol Infect. 2004;10:327–31.
  5. Fournier PE, Roux V, Caumes E, Donzel M, Raoult D. Outbreak of Rickettsia africae infections in participants of an adventure race from South Africa. Clin Infect Dis. 1998; 27:316–23.
  6. La Scola B, Rydkina L, Ndihokubwayo JB, Vene S, Raoult D. Serological differentiation of murine typhus and epidemic typhus using cross-adsorption and western blotting. Clin Diag Lab Immunol. 2000;7:612–6.
  7. La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to the diagnosis of old and new rickettsial diseases. J Clin Microbiol. 1997;35:2715–27.
  8. Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjoersdorff A, Blanco JR, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect, 2004;10:1108–32.
  9. Raoult D, Lakos A, Fenollar F, Beytout J, Brouqui P, Fournier PE. Spotless rickettsiosis caused by Rickettsia slovaca and associated with Dermacentor ticks. Clin Infect Dis. 2002;34:1331–6.
  10. Lakos A. Tick-borne lymphadenopathy—a new rickettsial disease? Lancet. 1997; 350:1006.

 

Appendix Table. Laboratory results for 14 patients with Rickettsia slovaca infection*


Patient

MIF assay

WB

Cross-adsorption

Culture

PCR




Acute-phase serum†

Convalescent-phase serum*

Skin biopsy

Tick

Skin biopsy

Tick

Acute phase serum


1

256/0

256/0

+

R. slovaca

NA

NA

2

0/32

NA

+

R. slovaca

NA

R. slovaca

NA

3

0/0

0/0

+

R. slovaca

R. slovaca

NA

R. slovaca

NA

4

0/0

0/0

NA

NA

R. slovaca

NA

R. slovaca

NA

5

0/0

32/32

+

R. slovaca

NA

NA

NA

NA

R. slovaca

6

0/32

0/32

+

R. slovaca

NA

NA

NA

NA

7

0/0

64/64

NA

NA

NA

R. slovaca

NA

R. slovaca

8

0/0

NA

+

R. slovaca

NA

NA

9

32/32

NA

+

R. slovaca

NA

NA

10

0/0

NA

NA

NA

NA

NA

NA

R. slovaca

11

0/0

NA

NA

NA

NA

NA

NA

NA

12

64/0

64/0

+

R. slovaca

R. slovaca

13

0/128

NA

+

R. slovaca

NA

NA

NA

NA

14

256/128

NA

+

R. slovaca

NA

NA

NA

NA


*MIF, microimmunofluorescence; WB, Western blot; PCR, polymerase chain reaction; NA, not available.

†Antibody titers are immunoglobulin G (IgG)/IgM against R. slovaca.

 

Suggested citation for this article:
Gouriet F, Rolain J-M, Raoult D. Rickettsia slovaca infection, France [letter].Emerg Infect Dis [serial on the Internet]. 2006 Mar [date cited]. Available from http://www.cdc.gov/ncidod/EID/vol12no03/05-0911.htm

   
     
   
Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Didier Raoult, Unité des Rickettsies, Faculté de Médecine, 27, Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France; fax: 33-4-91-38-77-72; email: Didier.Raoult@medecine.univ-mrs.fr

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Return email address optional:


 


Comments to the EID Editors
Please contact the EID Editors at eideditor@cdc.gov

Email this article

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Your email:

Your friend's email:

Message (optional):

 

 

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page posted February 17, 2006
This page last reviewed February 24, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention